Lab-on-Chip for testing myelotoxic effect of drugs and chemicals by Rasponi, Marco et al.
1 
Lab-on-Chip for Testing Myelotoxic Effect of 1 
Drugs and Chemicals 2 
 3 
 4 
 5 
Marco Rasponi 6 
Department of Electronics, Information and Bioengineering, Politecnico di 7 
Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy. 8 
+39(02)2399-3377 9 
+39(02)2399-3360 10 
marco.rasponi@polimi.it 11 
 12 
Andrea Gazaneo 13 
Department of Electronics, Information and Bioengineering, Politecnico di 14 
Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy. 15 
andrea.gazaneo@polimi.it 16 
 17 
Arianna Bonomi 18 
Department of Biomedical, Surgical and Dental Sciences, Università degli Studi 19 
di Milano, 20133 Milano, Italy. 20 
arianna.bonomi@unimi.it 21 
 22 
Andrea Ghiglietti 23 
Department of Mathematics “Francesco Brioschi”, Politecnico di Milano, 20133 24 
Milano, Italy. 25 
andrea.ghiglietti@polimi.it 26 
 27 
Paola Occhetta 28 
Department of Electronics, Information and Bioengineering, Politecnico di 29 
Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy. 30 
paola.occhetta@polimi.it 31 
 32 
2 
Gianfranco Beniamino Fiore 1 
Department of Electronics, Information and Bioengineering, Politecnico di 2 
Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy. 3 
gianfranco.fiore@polimi.it 4 
 5 
Augusto Pessina 6 
Department of Biomedical, Surgical and Dental Sciences, Università degli Studi 7 
di Milano, 20133 Milano, Italy. 8 
augusto.pessina@unimi.it 9 
 10 
Alberto Redaelli* 11 
Department of Electronics, Information and Bioengineering, Politecnico di 12 
Milano, Piazza Leonardo da Vinci 32, 20133 Milano, Italy. 13 
+39(02)2399-3375 14 
+39(02)2399-3360 15 
alberto.redaelli@polimi.it 16 
 17 
 18 
* Corresponding author 19 
 20 
 21 
22 
3 
Abstract 1 
In the last twenty years, one of the main goals in the drug discovery field has been the 2 
development of reliable in vitro models. In particular, in 2006 the European Centre for the 3 
Validation of Alternative Methods (ECVAM) has approved the Colony forming Unit-4 
Granulocytes-Macrophages (CFU-GM) test, which is the first and currently unique test applied to 5 
evaluate the myelotoxicity of xenobiotics in vitro. The present work aimed at miniaturizing this in 6 
vitro assay by developing and validating a Lab-on-Chip (LoC) platform consisting of a high 7 
number of bioreactor chambers with screening capabilities in a high-throughput regime. 8 
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1 Introduction 1 
In the last twenty years, one of the main goals in the drug discovery field has been 2 
the development of reliable in vitro models. Being currently the in vivo testing 3 
phase still necessary – to approve new drugs it is necessary to perform in vivo 4 
studies including at least two animal species, and employing various dosing 5 
schedules, depending on the molecule to be approved (Boorman et al. 1982) – 6 
research has been focusing on the development of new platforms able to replace, 7 
or reduce, the traditional in vivo trials at least in the early stages of the drug 8 
discovery process. Advantages of the in vitro approach mainly rely on economical 9 
and ethical standpoints. Indeed, in vitro testing presents numerous advantages, 10 
namely the reduction of model-to-model variability, ease of data collection, less 11 
requirements in terms of personnel training, reduction in the amounts of reagents, 12 
miniaturization and automation (Hartung and Daston 2009). 13 
One of the fields which could mainly benefit from the paradigm mutation towards 14 
in vitro experimentation is toxicology, i.e. the study of drug toxicity (Gad 1990). 15 
In particular, clonogenic assays are thought to better bridge the gap between 16 
toxicity experienced in vivo and toxicity effects on cells cultivated in laboratory 17 
(cytotoxicity). Clonogenic assays are cytotoxicity tests based on the rate of 18 
survival of colony forming units (CFUs) in the presence of several drug 19 
concentrations, thus differing from traditional proliferation assays which take into 20 
account the mere increase in cell number. Specific advantages of clonogenic 21 
assays are related to higher accuracy and predictivity with respect to traditional 22 
proliferation tests (Pessina et al. 2004). 23 
To date, the European Centre for Validation of Alternative Methods (ECVAM) 24 
has approved only one clonogenic test (DB-ALM protocol 101, available on 25 
http://ecvam-dbalm.jrc.ec.europa.eu/). This particular test aims at characterizing 26 
the acute effect of toxicants on granulocytes and macrophages (GM) progenitor 27 
cells derived both from bone marrow and umbilical cord blood, under maximally 28 
stimulatory cytokine concentrations. The system is based on counting CFUs 29 
formed by the surviving progenitors after xenobiotics exposure.  30 
In 2004, Pessina and co-workers optimized a new protocol for CFU-GM assay 31 
based on the use of 96-well plates in place of standard Petri dishes thus reducing 32 
complexity and costs of the original test. 33 
5 
However, the assay still remains time-consuming. Colonies are generally counted 1 
only upon 14 days of incubation. In addition, the assay implies the dispersion of 2 
cells within a semisolid culture medium, which inhibits a pre-determined 3 
localization of colonies (within dishes or wells), which all must be manually 4 
found by a trained operator (Pessina et al. 2001). 5 
Our goal was to develop a microfluidic device able to miniaturize the current 6 
state-of-art paradigm of in vitro hematotoxicity of xenobiotics protocol. Indeed, a 7 
further miniaturization of the original assay, down to the micrometer scale, will 8 
provide at the same time advantages in terms of cost reduction (cells, drugs, 9 
cytokines, etc.) and decrease of testing time (colony forming process). To this aim 10 
we designed a novel Lab-on-Chip (LoC) platform enabling for trapping, feeding 11 
and growing of multipotent monoclonal stem cells. 12 
2 Materials and Methods 13 
2.1 Lab-on-Chip design and fabrication 14 
A grid-like distribution of micro-chambers was envisaged within the LoC device 15 
to organize the spatial distribution of cells and, in turn, to obtain a univocal 16 
correspondence between colonies and culture chambers. 17 
For this purpose, we designed a microfluidic platform divided in two functional 18 
areas: a serial dilution generator (Jeon et al. 2002; Kim et al. 2008; Lee et al. 19 
2009; Occhetta et al. 2015a) and a culture region (Fig. 1). The first one consists of 20 
a fluidic network of channels (70µm high and 70µm wide) arranged in a resistive 21 
flow-based scheme to deliver six linear dilutions of drugs (concentration ranging 22 
from 1 to 0, step 0.2) from two input ports to the culture region. This area was 23 
integrated envisioning the possibility to test the cytotoxic effect of different dose 24 
of drugs on bone marrow progenitor cells within a single device.  25 
Downstream, the culture region consists of 180 cubic chambers (side 150µm) 26 
divided in 6 units, each composed by 3 parallel lines of ten culture chambers. 27 
The microfluidic device is made of polydimethylsiloxane (PDMS) and fabricated 28 
by means of standard soft lithography techniques. Briefly, a 4” silicon wafer, 29 
microstructured with two photoresist types, served as master mold to cast a thin 30 
layer (about 1mm) of liquid PDMS, being curing agent and pre-polymer mixed in 31 
a ratio 1:10 (w/w). A 3 hours thermal treatment at 65°C was applied to achieve a 32 
6 
complete crosslinking. Subsequently, the cured PDMS stamp was removed from 1 
the mold and bonded, upon an air plasma treatment, to a previously casted slab of 2 
PDMS (thickness 4 mm) to close the fluidic features. The assembly was trimmed 3 
and drilled in correspondence of 4 inputs and 6 outputs, by means of biopsy 4 
punchers having diameters of 0.5 and 3mm, respectively. Finally, the LoC device 5 
was bonded to a histology glass slide upon a further air plasma treatment, 6 
sterilized through autoclaving (121°C, 20 min, wet cycle) and subsequently dried 7 
overnight at 80°C to recover PDMS hydrophobicity after plasma treatment, thus 8 
minimizing cell adhesion. 9 
 10 
Fig. 1 The layout of the Lab-on-Chip device is shown together with a detail of a group of 11 
chambers within a culture unit. Two main input ports (together with two secondary ports) deliver 12 
dilutions of chemicals (100%, 80%, 60%, 40%, 20%, CTRL) to 6 culture units (30 chambers each) 13 
2.2 Cell expansion and characterization 14 
As a source of stem cells, the mononucleated cell fraction from human umbilical 15 
cord blood (CB-MNCs) purchased frozen from Lonza (Swiss) was used.  The 16 
cells, stored in liquid nitrogen until use, were thawed according to a previously 17 
described standard operating procedure (Pessina et al., 2004). Briefly, thawed 18 
cells were transferred from the cryovial to a 15 ml conical tube and swirled while 19 
warmed thawing medium (Iscove’s Modified Dulbecco Medium (IMDM) 20 
supplemented with 10% Fetal Bovine Serum (FBS) and 10 U/ml Dnase I) was 21 
added drop by drop to the cells. The cell suspension was then centrifuged at 200g 22 
for 15 min at room temperature. 23 
7 
Most of the wash was removed by pipette leaving 1–2 ml behind so the cell pellet 1 
was not disturbed and was then resuspended in the remaining medium. Fresh 2 
IMDM with 1% l-glutamine and 10% FBS was added to the cell suspension and 3 
then centrifuged as above described. All the reagents were purchased from 4 
EuroClone (Italy). Cells were then resuspended in Complete Medium (CM), 5 
consisting of IMDM, containing 30% FBS, 1% L-Glutamine, 1% 6 
Penicillin/Streptomycin solution and 10 ng/ml recombinant human granulocyte/ 7 
macrophage colony-stimulating factor (r hu GM-CSF, RELIATech, Germany) to 8 
evaluate their number and viability.  9 
Subsequently, CFU based tests were performed by using pooled donor cord 10 
blood-derived CD34+ cells, purchased frozen from Life Technologies, USA. The 11 
cells were stored and thawed according to the same protocol applied for CB-12 
MNCs. 13 
2.3 Cell seeding within the LoC platform 14 
Preliminary tests were carried out to establish a correlation between cell seeding 15 
conditions and number of cells trapped in each chamber. For this purpose CB 16 
MNCs were used. Aliquots of 30µl of cell suspension (concentration of 500,000 17 
cells/ml) were simultaneously injected into both input ports through a dual 18 
channel syringe pump at a flow rate of either 0.1 or 0.2 µl/min. Upon complete 19 
seeding, a picture of each chamber was taken through a phase contrast 20 
microscope, and the number of cells contained in each chamber was directly 21 
quantified. For these experiments, a number of 9 and 8 replicates (n=9 and n=8) 22 
were used for 0.1 and 0.2µl/min, respectively. 23 
 24 
 25 
Fig. 2. Content in terms of cell number for each of the 10 chambers encountered by cells in their 26 
stream. Each device has 18 decades of chambers, and experiments were carried out for 9 and 8 27 
8 
replicates for 0.1 and 0.2 µl/min flow rates, respectively. Data is presented as mean ± standard 1 
deviation 2 
 3 
The cell distribution for both conditions tested is depicted in Fig. 2, which shows 4 
a decrement in population along chambers in the same fluidic path. In particular, 5 
the number of cells present in each chamber at the end of the seeding process 6 
resulted 14.2 ± 26.2 and 16.8 ± 18.7 for flow rates of 0.1 and 0.2µl/min, 7 
respectively. Although these values were similar, the higher flow rate provided a 8 
significantly lower number of empty chambers (24.4 ± 22.8 vs 11.4 ± 9.5), while 9 
reducing the seeding time (2.5 vs 5 hours). Thus 0.2 µl/min was chosen as seeding 10 
condition for the following experiments and corresponding data were used in the 11 
statistical model. Immediately after seeding, CB MNCs viability within the device 12 
was estimated to be higher than 90% (see Supplementary Information). 13 
2.4 Statistical model of the clonogenic assay 14 
In general, the toxic effect of a drug molecule tested in a clonogenic assay results 15 
in a smaller number of CFUs with respect to a control condition, wherein no drug 16 
is administered. For a suitable statistical analysis, we modeled this situation as if 17 
the drug was able to decrease the probability of any single cell to be clonogenic, 18 
while keeping the number of cells constant. 19 
We denote with p0  the probability of any cell to form a colony in the control. This 20 
value does not depend on the chamber volume and it is also independent of time, 21 
thus it is an intrinsic property of the cell donor. According to the results obtained 22 
with standard macroscale experiments, in our case study p0 was set equal to 23 
1/146. We then set a hypothesis test to determine if there is statistical evidence to 24 
state whether the probability p of a cell to form a colony when drug is 25 
administered is smaller than the probability p0 in the control. Hence, in the null 26 
hypothesis we have p=p0, while in the alternative hypothesis we have p=p1<p0. 27 
The seeding process suggested us to model the number of cells injected in each 28 
chamber as a random variable with a probability distribution depending on the 29 
position of the chamber in the corresponding line. Moreover, the numbers of cells 30 
in the chambers were treated as independent variables, and all the lines and units 31 
were considered to have the same distribution of cells. From the data collected in 32 
the seeding characterization tests (Fig. 2, perfusion rate 0.2µl/min) we computed 33 
9 
the empirical distribution of the number of cells for each position within the 1 
culture line (constituted by 10 chambers). 2 
The probability to find a colony in a chamber was obtained by modelling the 3 
number of clonogenic cells per chamber with a binomial law, having size equal to 4 
the average number of cell in that chamber and probability equal to p0. Hence, the 5 
number of positive chambers (chambers+, i.e. chambers containing at least one 6 
colony) in a chip composed by n chambers (n/10 culture lines) is defined by a 7 
sum of n independent and identical distribution binomial random variables whose 8 
parameters are those defined above. Since the probability distribution of this 9 
random variable does not belong to any family of distributions known in statistics, 10 
its density cannot be expressed analytically but it must be computed through 11 
simulations.  These simulations were run through the R environment (software 12 
version 2.13.1), and a set of 10000 repetitions was enough to obtain stable 13 
distributions. 14 
A critical region for the hypothesis test was built as it follows: the null hypothesis 15 
(i.e. a cell is clonogenic with a probability equal to p0) has to be rejected 16 
whenever the number of chambers+ in the chip is less than a threshold C. The 17 
threshold value depends upon the significance level α of the test and the number 18 
of chambers in the chip n. For instance, by setting α=0.05, in our chip (n=180) we 19 
obtained C=12. 20 
Furthermore, we computed the power of the test for different values of p1, that is 21 
the probability of having less than C chambers+ due to the effect of the 22 
administered drug (p1<p0). In Fig. 3, for instance, we show the probability 23 
distribution of the chambers+ for a particular choice of p1 = 1/2p0 = 1/292, 24 
corresponding to the ideal IC50 for a drug molecule. In this case, the power 25 
resulted equal to 73.8%. 26 
 27 
 28 
10 
Fig. 3. Probability distributions of the number of chambers+ within the chip both when no drug 1 
(light grey; probability of proliferation p0=1/146) and a drug at a concentration corresponding to 2 
the IC50 (dark grey; p1=1/292) are administered. The vertical red line indicates the threshold 3 
C=12 used for the critical region of the test 4 
 5 
The power of the test computed above is only valid when the number of chambers 6 
in the chip is equal to 180. In Fig. 4 we show how the power of the test depends 7 
on n. The vertical red dotted line represents the current chip with n=180, whose 8 
power is equal to 0.738. The power rapidly approaches its maximum value when 9 
the number of chambers increases (it exceeds 0.9 already with n=240). 10 
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Fig. 4. Power of the test as a function of the number of chambers in the chip (n). The vertical red 12 
dotted line represents the current chip with n=180, whose power is equal to 0.738. 13 
2.5 Implementation of the microscale clonogenic assay 14 
CD34+ cells were seeded into the LoC device at a flow rate of 0.2 µl/min. Upon 15 
2.5 hours, CM was prepared and perfused into the device at the same flow rate 16 
11 
throughout the entire culture period (14 days), according to previous results in a 1 
similar platform (Occhetta et al. 2015b). At specific time points (days 1, 5, 7 and 2 
14) pictures from all culture chambers of the LoC device were taken to monitor 3 
possible variations in cell number. The results were compared to control 4 
experiments, consisting of devices perfused with culture medium free from 5 
cytokines. 6 
CFU potential of CD34+ cells within the microfluidic device was also assessed 7 
both in the absence and presence of a drug with a recognized hematotoxicity in 8 
clinical use. In particular, 1200 ng/ml (200X) of Paclitaxel (Toronto Research 9 
Chemicals, Canada) dissolved in dimethylsulfoxide (DMSO, Serva, Germany), 10 
were added to CM in order to have a final drug concentration of 6 ng/ml and a 11 
DMSO percentage of 0.5% (v/v). Paclitaxel was delivered to cells through the 12 
input ports through continuous perfusion. The culture was carried out up to 7 13 
days, and pictures of each chamber were taken at days 1, 5 and 7. Pictures from 14 
the control device were also taken at the same time-points and used as positive 15 
control. 16 
3 Results and Discussion 17 
The 2-weeks culture period within the microfluidic platform provided an 18 
increasing number of CD34+ cells in each chamber from day 1 to day 14 when 19 
perfused with CM with cytokines, being the initial number of cells per chamber 20 
13.1 ± 15.3 and the final 24.4 ± 21.0. Conversely, the number of cells did not 21 
change significantly along the culture period in the control experiment without 22 
cytokines (with a percentage increase of only 0.57%). 23 
In particular, we noticed an increased in the number of cells from day 1 to day 5 24 
(21.0 ± 19.0), thus suggesting the possibility to reduce the assay time by 25 
identifying the chamber containing colonies (positive chambers, chamber+) 26 
within a shorter five days period of culture in vitro. 27 
 28 
12 
 1 
Fig. 5. Examples of a chamber containing at least one CFU (top) and no CFU (bottom) 2 
 3 
The number of chamber+ was inferred from pictures for both conditions. Fig. 5 4 
shows the content of two exemplifying chambers. In particular, a chamber was set 5 
positive in case the following conditions were simultaneously true: 6 
 7 
i. relative cell number increase > 25%; 8 
ii. absolute cell number increase > 4. 9 
 10 
The number of resulting chamber+ was 15.33 ± 6.11 (n=3), in agreement with the 11 
statistical model. 12 
Furthermore, as preliminary test, the number of chamber+ was also assessed in 13 
presence of Paclitaxel, a prototype toxicant molecule whose dosage was chosen, 14 
in agreement with our previous findings corresponding to half maximal inhibitory 15 
concentration (IC50). The number of chamber+ in absence of any toxicant 16 
substances was 14 (positive control), while chamber+ number was reduced to 6 17 
when the drug was delivered. Fig. 6 shows a graphical representation of the 18 
distributions of chamber+ (green), chamber- (yellow) and empty chambers (red) 19 
for both cases. 20 
 21 
13 
 1 
Fig. 6. Representation of positive (green), negative (yellow) and empty (red) chambers 2 
 3 
This result suggests that the device, together with the implemented statistical 4 
model, allows identifying the toxicity of a test molecule at a specific 5 
concentration. 6 
4 Conclusions 7 
The proposed LoC device demonstrated its suitability as platform for CFU-based 8 
assays. The average number of colonies formed after five days of culture (15.33 ± 9 
6.11) was adequate to detect the presence of a toxic dosage (IC50) of a drug. The 10 
assay time was dramatically reduced in two ways: i) the culture time decreased 11 
from 14 to 5 days, and ii) the colony identification was reduced to microscopy 12 
acquisitions on a well-defined plane (chamber/channel fluidic layer). 13 
The device was provided with a serial dilution generator unit, able to precisely 14 
deliver to culture units predetermined concentration of soluble factors. However, 15 
the number of chambers implemented for these experiments (n=180) was only 16 
enough to catch the effect of a single test condition – namely the concentration of 17 
the administered molecule – and this unit was not used. Neverthless, by simply 18 
increasing the number of chambers contained in each culture unit (e.g. to 180 or 19 
more), the device could be exploited to fully implement a miniaturized clonogenic 20 
14 
test directly on-chip. As described, the increase of the number of culture chambers 1 
is also expected to improve the power of the statistical model; indeed, finer cutoff 2 
thresholds could be considered to exclude chambers initially containing a number 3 
of cells statistically different from the expected one. 4 
Remarkably, a straightforward integration of this miniaturized model with a real-5 
time acquisition system for the automatic detection and quantification of colonies, 6 
easily feasible thanks to the pre-determined and ordered positions of CFUs within 7 
the optically transparent device, would represent a huge step towards an automatic 8 
and user-friendly implementation of the clonogenic test. 9 
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